Peter Chang
- Pathology and Forensic Medicine top 0.5%
- Multiple Sclerosis Research Studies 12
- Rheumatology top 1%
-
- Prostate Cancer Diagnosis and Treatment 36
- Renal cell carcinoma treatment 27
- Prostate Cancer Treatment and Research 26
- Neurology top 2%
- Oncology top 5%
-
- Bladder and Urothelial Cancer Treatments 22
-
- Renal and related cancers 16
-
- Health Systems, Economic Evaluations, Quality of Life 9
-
- Urological Disorders and Treatments 8
- Co-authors
- Andrew A. WagnerPeter RieckmannKottil RammohanBruno MuschSteven J. GreenbergStuart D. CookAnthony HamlettPatrick Vermersch
- Journals
- The Journal of Urology (26 papers)Urologic Oncology Seminars and Original Investigations (11 papers)Urology (9 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Peter Chang
140 papers receiving 4.3k citations
Hit Papers
Peers
Comparison fields: 5 of 133
- Pathology and Forensic Medicine 1.4k
- Rheumatology 731
- Pulmonary and Respiratory Medicine 1.4k
- Neurology 519
- Oncology 781
Countries citing papers authored by Peter Chang
This map shows the geographic impact of Peter Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Chang more than expected).
Fields of papers citing papers by Peter Chang
This network shows the impact of papers produced by Peter Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Chang. The network helps show where Peter Chang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Peter Chang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 1 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 11 | |
| 6 | 2024 | 2 | |
| 7 | 2023 | 3 | |
| 8 | 2023 | 3 | |
| 9 | 2023 | 0 | |
| 10 | 2023 | 5 | |
| 11 | 2020 | 9 | |
| 12 | 2019 | 76 | |
| 13 | 2019 | 49 | |
| 14 | 2019 | 2 | |
| 15 | 2019 | 5 | |
| 16 | 2018 | 32 | |
| 17 | 2017 | 41 | |
| 18 | 2015 | 26 | |
| 19 | 2013 | 56 | |
| 20 | Tolerability profile of cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis: factors contributing to treatment completion overall and in patients with high disease activity in the 96-week CLARITY study | 2011 | 1 |
About Peter Chang
Peter Chang is a scholar working on Pulmonary and Respiratory Medicine, Urology and Rheumatology, having authored 151 papers that have together received 4.5k indexed citations. Recurring topics across this work include Prostate Cancer Diagnosis and Treatment (36 papers), Renal cell carcinoma treatment (27 papers), Prostate Cancer Treatment and Research (26 papers), Bladder and Urothelial Cancer Treatments (22 papers), Renal and related cancers (16 papers), Multiple Sclerosis Research Studies (12 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Urological Disorders and Treatments (8 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.4k citations), Rheumatology (731 citations) and Pulmonary and Respiratory Medicine (1.4k citations). Peter Chang has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Andrew A. Wagner, Peter Rieckmann, Kottil Rammohan, Bruno Musch, Steven J. Greenberg, Stuart D. Cook, Anthony Hamlett, Patrick Vermersch, Gavin Giovannoni and Per Soelberg Sørensen. Their work appears in journals such as The Journal of Urology, Urologic Oncology Seminars and Original Investigations, Urology, Journal of Clinical Oncology and Prostate Cancer and Prostatic Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.